Unanswered clinical questions and speculation about the role of anti–immunoglobulin E in atopic and nonatopic disease

Author: Lanier, Bob

Source: Allergy and Asthma Proceedings, Volume 27, Supplement 1, March-April 2006 , pp. 37-42(6)

Publisher: OceanSide Publications, Inc

Buy & download fulltext article:

OR

Price: $39.50 plus tax (Refund Policy)

Abstract:

As clinical experience with omalizumab increases, questions arise from clinicians that are not answered in the product insert or clinical reports. How does this drug really work? There surely must be more than the simple reduction of free IgE which, in and of itself, causes no disease. Can omalizumab be used in patients whose IgE level is below 30 or above 700 IU/mL? Can you treat a pregnant asthmatic woman with omalizumab? What are the updated risks for cancer? Is there a risk for omalizumab-treated patients who travel to parasite-endemic areas? What are the implications of skin-prick tests that remain positive after treatment? Does this drug prevent anaphylaxis with enough assurity to use it in conjunction with immunotherapy (IT) or rush IT? Are the complexes formed as a result of therapy problematic, therapeutic, or inconsequential? How long should this drug be used? It is the purpose of this review to examine these clinical issues and present common strategies for approaching each.

Document Type: Research Article

Publication date: March 1, 2006

More about this publication?
  • Allergy and Asthma Proceedings is a peer reviewed publication dedicated to distributing timely scientific research regarding advancements in the knowledge and practice of allergy, asthma and immunology. Its primary readership consists of allergists and pulmonologists.

    The goal of the Proceedings is to publish articles with a predominantly clinical focus which directly impact quality of care for patients with allergic disease and asthma.

    Featured topics include asthma, rhinitis, sinusitis, food allergies, allergic skin diseases, diagnostic techniques, allergens, and treatment modalities. Published material includes peer-reviewed original research, clinical trials and review articles.

    Articles marked "F" offer free full text for personal noncommercial use only.

    The journal is indexed in Thomson Reuters Web of Science and Science Citation Index Expanded, plus the National Library of Medicine's PubMed service.
  • Editorial Board
  • Information for Authors
  • Submit a Paper
  • Information for Advertisers
  • Reprint Requests
  • ingentaconnect is not responsible for the content or availability of external websites
Related content

Tools

Key

Free Content
Free content
New Content
New content
Open Access Content
Open access content
Subscribed Content
Subscribed content
Free Trial Content
Free trial content

Text size:

A | A | A | A
Share this item with others: These icons link to social bookmarking sites where readers can share and discover new web pages. print icon Print this page